6533b7ddfe1ef96bd1273c22
RESEARCH PRODUCT
Eribulin (E) and capecitabine (C), a combined treatment schedule in elderly metastatic breast cancer (EMBC): Efficacy and safety evaluation (E&S).
Dario CovaGiuseppe BrontePaolo FoaAntonio RussoIgnazio CarrecaViviana BazanPaolo D'aliasubject
OncologyCancer ResearchSchedulemedicine.medical_specialtyMicrotubule dynamicsMesylatebusiness.industrybacterial infections and mycosesmedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundCombined treatmentOncologychemistryInternal medicinepolycyclic compoundsmedicinebacteriaskin and connective tissue diseasesbusinessneoplasmsmedicine.drugEribulindescription
e20513 Background: E mesylate, a nontaxane microtubule dynamics inhibitor, was approved in the U.S in 2010 for the treatment of MBC who have previously received at least 2 MBC chemo regimens, inclu...
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-05-20 | Journal of Clinical Oncology |